Binge Eating Disorder – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Binge Eating Disorder – Pipeline Review, H1 2017’, provides an overview of the Binge Eating Disorder pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Binge Eating Disorder, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Binge Eating Disorder and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Binge Eating Disorder

The report reviews pipeline therapeutics for Binge Eating Disorder by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Binge Eating Disorder therapeutics and enlists all their major and minor projects

The report assesses Binge Eating Disorder therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Binge Eating Disorder

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Binge Eating Disorder

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Binge Eating Disorder pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Chronos Therapeutics Ltd

F. Hoffmann-La Roche Ltd

Heptares Therapeutics Ltd

Highland Therapeutics Inc

Omeros Corp

Opiant Pharmaceuticals Inc

Shire Plc

Sunovion Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Binge Eating Disorder - Overview

Binge Eating Disorder - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Binge Eating Disorder - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Binge Eating Disorder - Companies Involved in Therapeutics Development

Chronos Therapeutics Ltd

F. Hoffmann-La Roche Ltd

Heptares Therapeutics Ltd

Highland Therapeutics Inc

Omeros Corp

Opiant Pharmaceuticals Inc

Shire Plc

Sunovion Pharmaceuticals Inc

Binge Eating Disorder - Drug Profiles

amphetamine MR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CTDP-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dasotraline hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lisdexamfetamine dimesylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naloxone hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OMS-527 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RO-5256390 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Binge Eating Disorder - Dormant Projects

Binge Eating Disorder - Discontinued Products

Binge Eating Disorder - Product Development Milestones

Featured News & Press Releases

Jan 13, 2017: Sunovion Announces Top-line Results from Studies Evaluating Dasotraline in Adults with Binge Eating Disorder and Attention Deficit Hyperactivity Disorder

Oct 25, 2016: First And Only Medication Approved In Canada For The Treatment Of Binge Eating Disorder

Oct 17, 2016: Shire Announces Update to Vyvanse (lisdexamfetamine dimesylate) U.S. Labeling to Include New Longer-Term Maintenance of Efficacy Data in Adults with Moderate to Severe Binge Eating Disorder

Oct 06, 2016: Study Finds New Approach to Block Binge Eating

Apr 14, 2016: Shire Submits NDA to FDA for New Formulation of Vyvanse (lisdexamfetamine dimesylate) CII as Chewable Tablets

Jan 25, 2016: Sunovion Announces Results from a Study Evaluating the Abuse Potential of Investigational Drug Dasotraline

Jul 22, 2015: Vyvanse (lisdexamfetamine dimesylate) Positive Top-Line Results in Maintenance of Efficacy Study in Adults with Moderate to Severe Binge Eating Disorder

Jun 13, 2015: PTAB Invalidates Lucerne Biosciences' '813 Patent for the Treatment of Binge Eating Disorder with Lisdexamfetamine Dimesylate

May 11, 2015: Shire to Present New Research at American Psychiatric Association Annual Meeting

Jan 30, 2015: Vyvanse (lisdexamfetamine dimesylate) Capsules (CII) Becomes First and Only Treatment Approved by the FDA for Adults with Moderate to Severe Binge Eating Disorder

Sep 15, 2014: Shire Announces FDA Acceptance for Filing with Priority Review of Supplemental New Drug Application (sNDA) for Vyvanse (lisdexamfetamine dimesylate) Capsules (CII) for Adults with Binge Eating Disorder

Nov 05, 2013: Positive Top-line Results Shown for Vyvanse Capsules in Adults with Binge Eating Disorder

May 17, 2013: Shire To Present Scientific Data On Vyvanse At 166th APA Annual Meeting 2013

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Binge Eating Disorder, H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Binge Eating Disorder – Pipeline by Chronos Therapeutics Ltd, H1 2017

Binge Eating Disorder – Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Binge Eating Disorder – Pipeline by Heptares Therapeutics Ltd, H1 2017

Binge Eating Disorder – Pipeline by Highland Therapeutics Inc, H1 2017

Binge Eating Disorder – Pipeline by Omeros Corp, H1 2017

Binge Eating Disorder – Pipeline by Opiant Pharmaceuticals Inc, H1 2017

Binge Eating Disorder – Pipeline by Shire Plc, H1 2017

Binge Eating Disorder – Pipeline by Sunovion Pharmaceuticals Inc, H1 2017

Binge Eating Disorder – Dormant Projects, H1 2017

Binge Eating Disorder – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Binge Eating Disorder, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports